Omega Fund Management, LLC Long-Term Concentrated

Location: Boston, MA

CIK: 0001637359 · Show all filings

Period: Q2 2019 (← Previous) (Next →)

Filing Date: Aug 13, 2019

Total Value: $392M (100.0% shares, 0.0% debt)

Holdings (15)

GOSS Gossamer Bio 39.3%

Value $154M Shares 6,953,416 Est. Cost $20.85 Unrealized -8.3%

REPL Replimune Group 19.0%

Value $74.57M Shares 5,103,455 Est. Cost $17.53 Unrealized -17.5%

— Morphic Holding 15.0%

Value $58.86M Shares 2,969,582 Est. Cost $19.82 Unrealized —

— Translate Bio 7.9%

Value $30.79M Shares 2,437,603 Est. Cost $12.65 Unrealized —

IMUX Immunic 4.0%

Value $15.73M Shares 1,371,494 Est. Cost $13.14 Unrealized 0.0%

— ObsEva 2.9%

Value $11.3M Shares 999,364 Est. Cost $9.76 Unrealized —

— Paratek Pharmaceuticals 2.6%

Value $10.38M Shares 2,600,410 Est. Cost $34.18 Unrealized —

TRVI Trevi Therapeutics 2.4%

Value $9.476M Shares 1,263,408 Est. Cost $8.61 Unrealized 0.0%

— Prevail Therapeutics 2.3%

Value $8.83M Shares 668,908 Est. Cost $13.20 Unrealized —

— FibroGen 1.5%

Value $5.903M Shares 130,646 Est. Cost $27.34 Unrealized —

— Pieris Pharmaceuticals 0.9%

Value $3.546M Shares 754,457 Est. Cost $1.83 Unrealized —

— ESSA Pharma 0.7%

Value $2.658M Shares 1,084,848 Est. Cost $3.00 Unrealized —

— Jounce Therapeutics 0.7%

Value $2.623M Shares 529,965 Est. Cost $21.99 Unrealized —

— Cidara Therapeutics 0.6%

Value $2.535M Shares 1,508,794 Est. Cost $6.73 Unrealized —

SNNAQ Sienna Biopharmaceuticals 0.2%

Value $660K Shares 758,610 Est. Cost $21.95 Unrealized -92.9%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GOSS	Gossamer Bio	6,953,416	$154M	39.3%	$20.85	-8.3%	Common Stock	38341P102
REPL	Replimune Group	5,103,455	$74.57M	19.0%	$17.53	-17.5%	Common Stock	76029N106
—	Morphic Holding	2,969,582	$58.86M	15.0%	$19.82	—	Common Stock	61775R105
—	Translate Bio	2,437,603	$30.79M	7.9%	$12.65	—	Common Stock	89374L104
IMUX	Immunic	1,371,494	$15.73M	4.0%	$13.14	0.0%	Common Stock	4525EP101
—	ObsEva	999,364	$11.3M	2.9%	$9.76	—	Common Stock	H5861P103
—	Paratek Pharmaceuticals	2,600,410	$10.38M	2.6%	$34.18	—	Common Stock	699374302
TRVI	Trevi Therapeutics	1,263,408	$9.476M	2.4%	$8.61	0.0%	Common Stock	89532M101
—	Prevail Therapeutics	668,908	$8.83M	2.3%	$13.20	—	Common Stock	74140Y101
—	FibroGen	130,646	$5.903M	1.5%	$27.34	—	Common Stock	31572Q808
—	Pieris Pharmaceuticals	754,457	$3.546M	0.9%	$1.83	—	Common Stock	720795103
—	ESSA Pharma	1,084,848	$2.658M	0.7%	$3.00	—	Common Stock	29668H708
—	Jounce Therapeutics	529,965	$2.623M	0.7%	$21.99	—	Common Stock	481116101
—	Cidara Therapeutics	1,508,794	$2.535M	0.6%	$6.73	—	Common Stock	171757107
SNNAQ	Sienna Biopharmaceuticals	758,610	$660K	0.2%	$21.95	-92.9%	Common Stock	82622H108